Tirzeptide
Research Overview

Tirzepatide is a synthetic peptide and dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor. During development it was known as LY3298176.

Research Context

Tirzepatide has been extensively studied in clinical trials investigating glucose regulation, body weight, metabolic
function, and the combined effects of GIPR and GLP-1R activation. Unlike retatrutide, tirzepatide is not investigational as an active ingredient: FDA-approved tirzepatide medicines are available for specific clinical indications. A separately supplied research-grade product should not be represented as an approved medicine.

Common Analytical Research Areas
  • GIPR and GLP-1R binding and signaling
  • Dual-agonist structure–activity and receptor selectivity
  • Peptide identity, purity, stability, and degradation analysis
  • Metabolic and glucose-regulation pathway research
Selected Scientific References

Research-use notice: Supplied exclusively for laboratory research and analytical use. Not for human or veterinary use, diagnosis, treatment, food, cosmetic, or household use.

Specification record updated 17 Sept 2026. External database links are provided for research context; verify primary sources before analytical use.

Medicine & Drugs

Tirzeptide

Overview

Dual GIP / GLP-1 receptor agonist — a potent research peptide studied for weight management and metabolic regulation.

Rs. 3,999.00
Request Certificate of Analysis
Get the third-party COA for this product via WhatsApp
❯
Product Specifications
Product class Dual GIP / GLP-1 receptor agonist peptide
Research name Tirzepatide / LY3298176
Available sizes 5 mg, 10 mg, 20 mg
Regulatory status Tirzepatide is an approved active pharmaceutical ingredient in FDA-approved medicines
Purity >99% by HPLC
Intended use Laboratory research only
Research Overview

Tirzepatide is a synthetic peptide and dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor. During development it was known as LY3298176.

Research Context

Tirzepatide has been extensively studied in clinical trials investigating glucose regulation, body weight, metabolic
function, and the combined effects of GIPR and GLP-1R activation. Unlike retatrutide, tirzepatide is not investigational as an active ingredient: FDA-approved tirzepatide medicines are available for specific clinical indications. A separately supplied research-grade product should not be represented as an approved medicine.

Common Analytical Research Areas
  • GIPR and GLP-1R binding and signaling
  • Dual-agonist structure–activity and receptor selectivity
  • Peptide identity, purity, stability, and degradation analysis
  • Metabolic and glucose-regulation pathway research
Selected Scientific References

Research-use notice: Supplied exclusively for laboratory research and analytical use. Not for human or veterinary use, diagnosis, treatment, food, cosmetic, or household use.

Specification record updated 17 Sept 2026. External database links are provided for research context; verify primary sources before analytical use.

Uses

Weight losss

Appetite control

Metabolic health

Research use Laboratory supply only
Batch verified COA per batch, always
India dispatch Secure checkout and tracking

You may also like